NCT02955160View on ClinicalTrials.gov

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 3, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

Multivalent

Pneumococcal conjugate vaccine

BIOLOGICAL

Tdap

Tetanus, diphtheria, and pertussis vaccine

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02955160 - A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years | Biotech Hunter | Biotech Hunter